Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
Voluntarily participate in the study and signed the ICF;
Male or female, aged 18-75 years;
All participants to be enrolled must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced (stage IIIB/IIIC )or recurrent metastatic NSCLC (stage IV ) and not amendable to curative surgery or radiation as assessed by investigator;
For previously locally advanced or recurrent metastatic disease not treated with systemic antitumor therapy;
Subjects with the presence of meningeal metastases, spinal cord compression, or active brain metastases；
Received ADC or MET inhibitors；
Suffering from refractory nausea and vomiting, chronic gastrointestinal disorders, inability to swallow pharmaceutical preparations, or previous major bowel resection that may prevent adequate absorption, distribution, metabolism, or excretion of oral medications;
Subjects with uncontrolled tumor-related pain；
Parallel
RC108
DrugRC108 in Combination With Furmonertinib
Furmonertinib Mesilate Tablets Monotherapy
DrugFurmonertinib
Objective Response Rate (ORR)
Investigator-assessed ORR
Progression-free survival (PFS)
Investigator-assessed PFS
Disease Control Rate (DCR)
Investigator-assessed DCR
Duration of Response (DoR)
Investigator-assessed DoR
Overall survival (OS)
Investigator-assessed OS
Click on the lead sponsor to view all of their trials.
